uniQure purchased the assets of AMT in April 2012, making it one of the world leaders in gene therapy research and development. Its Glybera® product is the first gene therapy drug to have gained marketing approval in Europe, and is used to treat adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD), a rare condition in which patients do not have the gene for an enzyme responsible for breaking down fats.
uniQure is developing products to treat various other conditions such as Haemophilia B, acute intermittent porphyria (AIP) and Parkinson’s disease.
February 2014: uniQure (QURE) successfully completed its IPO on the Nasdaq, raising $82 million.
Market capitalisation at IPO date: $300 million